United States Carcinoid Syndrome Management Market Report 2017

Name: United States Carcinoid Syndrome Management Market Report 2017
Brand: QYResearch
SKU: U92F9EE9D7AEN
Price: 3800 USD
Availability: InStock

May 2017 | 98 pages | ID: U92F9EE9D7AEN
QYResearch

US$ 3,800.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer

Checkout Later

Need Help? Ask a Question

In this report, the United States Carcinoid Syndrome Management market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:

The West
Southwest
The Middle Atlantic
New England
The South
The Midwest
with sales (volume), revenue (value), market share and growth rate of Carcinoid Syndrome Management in these regions, from 2012 to 2022 (forecast).

United States Carcinoid Syndrome Management market competition by top manufacturers/players, with Carcinoid Syndrome Management sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including

Novartis International AG (Sandoz)
Pharmascience Inc.
Omega Laboratories Ltd.
Teva Pharmaceutical Industries Ltd.
Mylan NV
Ipsen Biopharmaceuticals
Sirtex Medical Limited
BTG International Ltd.

On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into

Chemotherapy
Biological Therapy
Hepatic Artery Embolization Agents

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Carcinoid Syndrome Management for each application, including

Hospital pharmacy
Retail Pharmacy
Prescription Drug Stores

If you have any special requirements, please let us know and we will offer you the report as you want.

United States Carcinoid Syndrome Management Market Report 2017

1 CARCINOID SYNDROME MANAGEMENT OVERVIEW

1.1 Product Overview and Scope of Carcinoid Syndrome Management
1.2 Classification of Carcinoid Syndrome Management by Product Category
  1.2.1 United States Carcinoid Syndrome Management Market Size (Sales Volume) Comparison by Type (2012-2022)
  1.2.2 United States Carcinoid Syndrome Management Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
  1.2.3 Chemotherapy
  1.2.4 Biological Therapy
  1.2.5 Hepatic Artery Embolization Agents
1.3 United States Carcinoid Syndrome Management Market by Application/End Users
  1.3.1 United States Carcinoid Syndrome Management Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
  1.3.2 Hospital pharmacy
  1.3.3 Retail Pharmacy
  1.3.4 Prescription Drug Stores
1.4 United States Carcinoid Syndrome Management Market by Region
  1.4.1 United States Carcinoid Syndrome Management Market Size (Value) Comparison by Region (2012-2022)
  1.4.2 The West Carcinoid Syndrome Management Status and Prospect (2012-2022)
  1.4.3 Southwest Carcinoid Syndrome Management Status and Prospect (2012-2022)
  1.4.4 The Middle Atlantic Carcinoid Syndrome Management Status and Prospect (2012-2022)
  1.4.5 New England Carcinoid Syndrome Management Status and Prospect (2012-2022)
  1.4.6 The South Carcinoid Syndrome Management Status and Prospect (2012-2022)
  1.4.7 The Midwest Carcinoid Syndrome Management Status and Prospect (2012-2022)
1.5 United States Market Size (Value and Volume) of Carcinoid Syndrome Management (2012-2022)
  1.5.1 United States Carcinoid Syndrome Management Sales and Growth Rate (2012-2022)
  1.5.2 United States Carcinoid Syndrome Management Revenue and Growth Rate (2012-2022)

2 UNITED STATES CARCINOID SYNDROME MANAGEMENT MARKET COMPETITION BY PLAYERS/SUPPLIERS

2.1 United States Carcinoid Syndrome Management Sales and Market Share of Key Players/Suppliers (2012-2017)
2.2 United States Carcinoid Syndrome Management Revenue and Share by Players/Suppliers (2012-2017)
2.3 United States Carcinoid Syndrome Management Average Price by Players/Suppliers (2012-2017)
2.4 United States Carcinoid Syndrome Management Market Competitive Situation and Trends
  2.4.1 United States Carcinoid Syndrome Management Market Concentration Rate
  2.4.2 United States Carcinoid Syndrome Management Market Share of Top 3 and Top 5 Players/Suppliers
  2.4.3 Mergers & Acquisitions, Expansion in United States Market
2.5 United States Players/Suppliers Carcinoid Syndrome Management Manufacturing Base Distribution, Sales Area, Product Type

3 UNITED STATES CARCINOID SYNDROME MANAGEMENT SALES (VOLUME) AND REVENUE (VALUE) BY REGION (2012-2017)

3.1 United States Carcinoid Syndrome Management Sales and Market Share by Region (2012-2017)
3.2 United States Carcinoid Syndrome Management Revenue and Market Share by Region (2012-2017)
3.3 United States Carcinoid Syndrome Management Price by Region (2012-2017)

4 UNITED STATES CARCINOID SYNDROME MANAGEMENT SALES (VOLUME) AND REVENUE (VALUE) BY TYPE (PRODUCT CATEGORY) (2012-2017)

4.1 United States Carcinoid Syndrome Management Sales and Market Share by Type (Product Category) (2012-2017)
4.2 United States Carcinoid Syndrome Management Revenue and Market Share by Type (2012-2017)
4.3 United States Carcinoid Syndrome Management Price by Type (2012-2017)
4.4 United States Carcinoid Syndrome Management Sales Growth Rate by Type (2012-2017)

5 UNITED STATES CARCINOID SYNDROME MANAGEMENT SALES (VOLUME) BY APPLICATION (2012-2017)

5.1 United States Carcinoid Syndrome Management Sales and Market Share by Application (2012-2017)
5.2 United States Carcinoid Syndrome Management Sales Growth Rate by Application (2012-2017)
5.3 Market Drivers and Opportunities

6 UNITED STATES CARCINOID SYNDROME MANAGEMENT PLAYERS/SUPPLIERS PROFILES AND SALES DATA

6.1 Novartis International AG (Sandoz)
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Carcinoid Syndrome Management Product Category, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 Novartis International AG (Sandoz) Carcinoid Syndrome Management Sales, Revenue, Price and Gross Margin (2012-2017)
  6.1.4 Main Business/Business Overview
6.2 Pharmascience Inc.
  6.2.2 Carcinoid Syndrome Management Product Category, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 Pharmascience Inc. Carcinoid Syndrome Management Sales, Revenue, Price and Gross Margin (2012-2017)
  6.2.4 Main Business/Business Overview
6.3 Omega Laboratories Ltd.
  6.3.2 Carcinoid Syndrome Management Product Category, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 Omega Laboratories Ltd. Carcinoid Syndrome Management Sales, Revenue, Price and Gross Margin (2012-2017)
  6.3.4 Main Business/Business Overview
6.4 Teva Pharmaceutical Industries Ltd.
  6.4.2 Carcinoid Syndrome Management Product Category, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 Teva Pharmaceutical Industries Ltd. Carcinoid Syndrome Management Sales, Revenue, Price and Gross Margin (2012-2017)
  6.4.4 Main Business/Business Overview
6.5 Mylan NV
  6.5.2 Carcinoid Syndrome Management Product Category, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 Mylan NV Carcinoid Syndrome Management Sales, Revenue, Price and Gross Margin (2012-2017)
  6.5.4 Main Business/Business Overview
6.6 Ipsen Biopharmaceuticals
  6.6.2 Carcinoid Syndrome Management Product Category, Application and Specification
    6.6.2.1 Product A
    6.6.2.2 Product B
  6.6.3 Ipsen Biopharmaceuticals Carcinoid Syndrome Management Sales, Revenue, Price and Gross Margin (2012-2017)
  6.6.4 Main Business/Business Overview
6.7 Sirtex Medical Limited
  6.7.2 Carcinoid Syndrome Management Product Category, Application and Specification
    6.7.2.1 Product A
    6.7.2.2 Product B
  6.7.3 Sirtex Medical Limited Carcinoid Syndrome Management Sales, Revenue, Price and Gross Margin (2012-2017)
  6.7.4 Main Business/Business Overview
6.8 BTG International Ltd.
  6.8.2 Carcinoid Syndrome Management Product Category, Application and Specification
    6.8.2.1 Product A
    6.8.2.2 Product B
  6.8.3 BTG International Ltd. Carcinoid Syndrome Management Sales, Revenue, Price and Gross Margin (2012-2017)
  6.8.4 Main Business/Business Overview

7 CARCINOID SYNDROME MANAGEMENT MANUFACTURING COST ANALYSIS

7.1 Carcinoid Syndrome Management Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Carcinoid Syndrome Management

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Carcinoid Syndrome Management Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Carcinoid Syndrome Management Major Manufacturers in 2016
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 UNITED STATES CARCINOID SYNDROME MANAGEMENT MARKET SIZE (VALUE AND VOLUME) FORECAST (2017-2022)

11.1 United States Carcinoid Syndrome Management Sales Volume, Revenue Forecast (2017-2022)
11.2 United States Carcinoid Syndrome Management Sales Volume Forecast by Type (2017-2022)
11.3 United States Carcinoid Syndrome Management Sales Volume Forecast by Application (2017-2022)
11.4 United States Carcinoid Syndrome Management Sales Volume Forecast by Region (2017-2022)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer

The report requires updating with new data and is sent in 2-3 business days after order is placed.

LIST OF TABLES AND FIGURES

Figure Product Picture of Carcinoid Syndrome Management
Figure United States Carcinoid Syndrome Management Market Size (K Units) by Type (2012-2022)
Figure United States Carcinoid Syndrome Management Sales Volume Market Share by Type (Product Category) in 2016
Figure Chemotherapy Product Picture
Figure Biological Therapy Product Picture
Figure Hepatic Artery Embolization Agents Product Picture
Figure United States Carcinoid Syndrome Management Market Size (K Units) by Application (2012-2022)
Figure United States Sales Market Share of Carcinoid Syndrome Management by Application in 2016
Figure Hospital pharmacy Examples
Figure Retail Pharmacy Examples
Figure Prescription Drug Stores Examples
Figure United States Carcinoid Syndrome Management Market Size (Million USD) by Region (2012-2022)
Figure The West Carcinoid Syndrome Management Revenue (Million USD) and Growth Rate (2012-2022)
Figure Southwest Carcinoid Syndrome Management Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Middle Atlantic Carcinoid Syndrome Management Revenue (Million USD) and Growth Rate (2012-2022)
Figure New England Carcinoid Syndrome Management Revenue (Million USD) and Growth Rate (2012-2022)
Figure The South of US Carcinoid Syndrome Management Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Midwest Carcinoid Syndrome Management Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Carcinoid Syndrome Management Sales (K Units) and Growth Rate (2012-2022)
Figure United States Carcinoid Syndrome Management Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Carcinoid Syndrome Management Market Major Players Product Sales Volume (K Units) (2012-2017)
Table United States Carcinoid Syndrome Management Sales (K Units) of Key Players/Suppliers (2012-2017)
Table United States Carcinoid Syndrome Management Sales Share by Players/Suppliers (2012-2017)
Figure 2016 United States Carcinoid Syndrome Management Sales Share by Players/Suppliers
Figure 2017 United States Carcinoid Syndrome Management Sales Share by Players/Suppliers
Figure United States Carcinoid Syndrome Management Market Major Players Product Revenue (Million USD) (2012-2017)
Table United States Carcinoid Syndrome Management Revenue (Million USD) by Players/Suppliers (2012-2017)
Table United States Carcinoid Syndrome Management Revenue Share by Players/Suppliers (2012-2017)
Figure 2016 United States Carcinoid Syndrome Management Revenue Share by Players/Suppliers
Figure 2017 United States Carcinoid Syndrome Management Revenue Share by Players/Suppliers
Table United States Market Carcinoid Syndrome Management Average Price (USD/Unit) of Key Players/Suppliers (2012-2017)
Figure United States Market Carcinoid Syndrome Management Average Price (USD/Unit) of Key Players/Suppliers in 2016
Figure United States Carcinoid Syndrome Management Market Share of Top 3 Players/Suppliers
Figure United States Carcinoid Syndrome Management Market Share of Top 5 Players/Suppliers
Table United States Players/Suppliers Carcinoid Syndrome Management Manufacturing Base Distribution and Sales Area
Table United States Players/Suppliers Carcinoid Syndrome Management Product Category
Table United States Carcinoid Syndrome Management Sales (K Units) by Region (2012-2017)
Table United States Carcinoid Syndrome Management Sales Share by Region (2012-2017)
Figure United States Carcinoid Syndrome Management Sales Share by Region (2012-2017)
Figure United States Carcinoid Syndrome Management Sales Market Share by Region in 2016
Table United States Carcinoid Syndrome Management Revenue (Million USD) and Market Share by Region (2012-2017)
Table United States Carcinoid Syndrome Management Revenue Share by Region (2012-2017)
Figure United States Carcinoid Syndrome Management Revenue Market Share by Region (2012-2017)
Figure United States Carcinoid Syndrome Management Revenue Market Share by Region in 2016
Table United States Carcinoid Syndrome Management Price (USD/Unit) by Region (2012-2017)
Table United States Carcinoid Syndrome Management Sales (K Units) by Type (2012-2017)
Table United States Carcinoid Syndrome Management Sales Share by Type (2012-2017)
Figure United States Carcinoid Syndrome Management Sales Share by Type (2012-2017)
Figure United States Carcinoid Syndrome Management Sales Market Share by Type in 2016
Table United States Carcinoid Syndrome Management Revenue (Million USD) and Market Share by Type (2012-2017)
Table United States Carcinoid Syndrome Management Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Carcinoid Syndrome Management by Type (2012-2017)
Figure Revenue Market Share of Carcinoid Syndrome Management by Type in 2016
Table United States Carcinoid Syndrome Management Price (USD/Unit) by Types (2012-2017)
Figure United States Carcinoid Syndrome Management Sales Growth Rate by Type (2012-2017)
Table United States Carcinoid Syndrome Management Sales (K Units) by Application (2012-2017)
Table United States Carcinoid Syndrome Management Sales Market Share by Application (2012-2017)
Figure United States Carcinoid Syndrome Management Sales Market Share by Application (2012-2017)
Figure United States Carcinoid Syndrome Management Sales Market Share by Application in 2016
Table United States Carcinoid Syndrome Management Sales Growth Rate by Application (2012-2017)
Figure United States Carcinoid Syndrome Management Sales Growth Rate by Application (2012-2017)
Table Novartis International AG (Sandoz) Basic Information List
Table Novartis International AG (Sandoz) Carcinoid Syndrome Management Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Novartis International AG (Sandoz) Carcinoid Syndrome Management Sales Growth Rate (2012-2017)
Figure Novartis International AG (Sandoz) Carcinoid Syndrome Management Sales Market Share in United States (2012-2017)
Figure Novartis International AG (Sandoz) Carcinoid Syndrome Management Revenue Market Share in United States (2012-2017)
Table Pharmascience Inc. Basic Information List
Table Pharmascience Inc. Carcinoid Syndrome Management Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Pharmascience Inc. Carcinoid Syndrome Management Sales Growth Rate (2012-2017)
Figure Pharmascience Inc. Carcinoid Syndrome Management Sales Market Share in United States (2012-2017)
Figure Pharmascience Inc. Carcinoid Syndrome Management Revenue Market Share in United States (2012-2017)
Table Omega Laboratories Ltd. Basic Information List
Table Omega Laboratories Ltd. Carcinoid Syndrome Management Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Omega Laboratories Ltd. Carcinoid Syndrome Management Sales Growth Rate (2012-2017)
Figure Omega Laboratories Ltd. Carcinoid Syndrome Management Sales Market Share in United States (2012-2017)
Figure Omega Laboratories Ltd. Carcinoid Syndrome Management Revenue Market Share in United States (2012-2017)
Table Teva Pharmaceutical Industries Ltd. Basic Information List
Table Teva Pharmaceutical Industries Ltd. Carcinoid Syndrome Management Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Teva Pharmaceutical Industries Ltd. Carcinoid Syndrome Management Sales Growth Rate (2012-2017)
Figure Teva Pharmaceutical Industries Ltd. Carcinoid Syndrome Management Sales Market Share in United States (2012-2017)
Figure Teva Pharmaceutical Industries Ltd. Carcinoid Syndrome Management Revenue Market Share in United States (2012-2017)
Table Mylan NV Basic Information List
Table Mylan NV Carcinoid Syndrome Management Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Mylan NV Carcinoid Syndrome Management Sales Growth Rate (2012-2017)
Figure Mylan NV Carcinoid Syndrome Management Sales Market Share in United States (2012-2017)
Figure Mylan NV Carcinoid Syndrome Management Revenue Market Share in United States (2012-2017)
Table Ipsen Biopharmaceuticals Basic Information List
Table Ipsen Biopharmaceuticals Carcinoid Syndrome Management Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Ipsen Biopharmaceuticals Carcinoid Syndrome Management Sales Growth Rate (2012-2017)
Figure Ipsen Biopharmaceuticals Carcinoid Syndrome Management Sales Market Share in United States (2012-2017)
Figure Ipsen Biopharmaceuticals Carcinoid Syndrome Management Revenue Market Share in United States (2012-2017)
Table Sirtex Medical Limited Basic Information List
Table Sirtex Medical Limited Carcinoid Syndrome Management Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Sirtex Medical Limited Carcinoid Syndrome Management Sales Growth Rate (2012-2017)
Figure Sirtex Medical Limited Carcinoid Syndrome Management Sales Market Share in United States (2012-2017)
Figure Sirtex Medical Limited Carcinoid Syndrome Management Revenue Market Share in United States (2012-2017)
Table BTG International Ltd. Basic Information List
Table BTG International Ltd. Carcinoid Syndrome Management Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure BTG International Ltd. Carcinoid Syndrome Management Sales Growth Rate (2012-2017)
Figure BTG International Ltd. Carcinoid Syndrome Management Sales Market Share in United States (2012-2017)
Figure BTG International Ltd. Carcinoid Syndrome Management Revenue Market Share in United States (2012-2017)
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Carcinoid Syndrome Management
Figure Manufacturing Process Analysis of Carcinoid Syndrome Management
Figure Carcinoid Syndrome Management Industrial Chain Analysis
Table Raw Materials Sources of Carcinoid Syndrome Management Major Players/Suppliers in 2016
Table Major Buyers of Carcinoid Syndrome Management
Table Distributors/Traders List
Figure United States Carcinoid Syndrome Management Sales Volume (K Units) and Growth Rate Forecast (2017-2022)
Figure United States Carcinoid Syndrome Management Revenue (Million USD) and Growth Rate Forecast (2017-2022)
Figure United States Carcinoid Syndrome Management Price (USD/Unit) Trend Forecast (2017-2022)
Table United States Carcinoid Syndrome Management Sales Volume (K Units) Forecast by Type (2017-2022)
Figure United States Carcinoid Syndrome Management Sales Volume (K Units) Forecast by Type (2017-2022)
Figure United States Carcinoid Syndrome Management Sales Volume (K Units) Forecast by Type in 2022
Table United States Carcinoid Syndrome Management Sales Volume (K Units) Forecast by Application (2017-2022)
Figure United States Carcinoid Syndrome Management Sales Volume (K Units) Forecast by Application (2017-2022)
Figure United States Carcinoid Syndrome Management Sales Volume (K Units) Forecast by Application in 2022
Table United States Carcinoid Syndrome Management Sales Volume (K Units) Forecast by Region (2017-2022)
Table United States Carcinoid Syndrome Management Sales Volume Share Forecast by Region (2017-2022)
Figure United States Carcinoid Syndrome Management Sales Volume Share Forecast by Region (2017-2022)
Figure United States Carcinoid Syndrome Management Sales Volume Share Forecast by Region in 2022
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources

United States Carcinoid Syndrome Management Market Report 2017

More Publications

Need Help?

Ask a Question

Market Reports